Royal Bank Of Canada Galera Therapeutics, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.14 - $0.27 $58 - $113	-421 Reduced 1.18%	35,403 $4,000
Q4 2023 Feb 14, 2024	BUY	$0.09 - $0.27 $65 - $197	732 Added 2.09%	35,824 $5,000
Q3 2023 Nov 14, 2023	BUY	$0.17 - $3.0 $2,235 - $39,447	13,149 Added 59.92%	35,092 $6,000
Q2 2023 Aug 14, 2023	BUY	$2.5 - $3.42 $30,137 - $41,228	12,055 Added 121.92%	21,943 $68,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.68 $3,238 - $5,863	2,188 Added 28.42%	9,888 $25,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.78 $2,417 - $3,211	-1,804 Reduced 18.98%	7,700 $11,000
Q3 2022 Nov 14, 2022	BUY	$1.15 - $2.1 $338 - $617	294 Added 3.19%	9,504 $16,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $53 - $102	-43 Reduced 0.46%	9,210 $12,000
Q1 2022 May 16, 2022	SELL	$2.01 - $4.19 $1,250 - $2,606	-622 Reduced 6.3%	9,253 $22,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $8.28 $2,762 - $18,009	2,175 Added 28.25%	9,875 $45,000
Q3 2021 Nov 15, 2021	BUY	$7.04 - $10.49 $52,208 - $77,793	7,416 Added 2611.27%	7,700 $62,000
Q2 2021 Aug 16, 2021	BUY	$6.08 - $10.44 $1,726 - $2,964	284 New	284 $3,000

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.34M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.